Estimations des analystes de Wall Street pour Myriad Genetics, Inc. (MYGN): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.16 | ||
| 2026-07-30 | $-0.25 | $-0.06 | -331.9% |
| 2026-05-05 | $-0.09 | $-0.06 | -50.0% |
| 2026-02-23 | $0.04 | $-0.02 | +300.0% |
| 2025-11-03 | $-0.13 | $-0.01 | -1200.0% |
| 2025-08-05 | $0.05 | $-0.01 | +600.0% |
| 2025-05-06 | $-0.03 | $-0.05 | +40.0% |
| 2025-02-24 | $0.03 | $0.03 | +0.0% |
Ratios de valorisation
| Prix / Valeur comptable | 1.27 |
| EV / EBITDA | -9.25 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $728.7M | $743.7M | $851.1M | $638.6M | $557.0M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Coût des Ventes | $171.2M | $177.2M | $201.0M | $186.1M | $178.2M | $197.6M | $202.0M | $236.2M | $252.2M | $247.9M |
| Marge Brute | $557.5M | $566.5M | $650.1M | $452.5M | $378.8M | $493.0M | $476.4M | $517.0M | $585.4M | $576.6M |
| R&D | $74.4M | $70.8M | $85.9M | $77.2M | $80.9M | $81.9M | $85.4M | $88.7M | $113.4M | $106.8M |
| Frais Généraux | $439.9M | $435.0M | $556.6M | $507.3M | $500.7M | $537.8M | $514.7M | $572.9M | $560.0M | $537.6M |
| Charges Opérationnelles | $513.5M | $444.6M | $642.5M | $684.2M | $653.3M | $683.5M | $600.1M | $661.6M | $673.4M | $644.4M |
| Résultat Opérationnel | $44.0M | $121.9M | $7.6M | -$231.7M | -$194.8M | -$190.5M | -$123.7M | -$144.6M | -$88.0M | -$67.8M |
| EBITDA | $90.5M | $177.7M | $85.0M | -$140.5M | -$123.4M | $12.3M | -$84.7M | -$197.4M | -$59.5M | -$330.9M |
| Charges d'Intérêt | $6.0M | $3.2M | $12.0M | $10.8M | 0 | $6.6M | $3.2M | $2.9M | $2.8M | $10.5M |
| Résultat Avant Impôts | $36.2M | $120.1M | 0 | -$223.3M | -$283.7M | -$57.1M | -$140.6M | -$262.2M | -$123.5M | -$395.1M |
| Impôts | $19.0M | -$13.0M | -$4.4M | -$23.7M | -$59.9M | -$29.9M | -$28.6M | $1.1M | $3.8M | -$29.2M |
| Résultat Net | $17.4M | $133.3M | $4.6M | -$199.5M | -$223.7M | -$27.2M | -$112.0M | -$263.3M | -$127.3M | -$365.9M |
| BPA | $0.32 | $1.89 | $0.06 | $-2.69 | $-2.99 | $-0.35 | $-1.39 | $-3.18 | $-1.41 | $-3.96 |
| BPA Dilué | $0.32 | $1.82 | $0.06 | $-2.69 | $-2.99 | $-0.35 | $-1.39 | $-3.18 | $-1.41 | $-3.96 |
| Actions en Circulation (Diluées) | $68.8M | $72.0M | $76.0M | $74.3M | $74.8M | $78.0M | $80.6M | $82.8M | $90.6M | $93.3M |
Prix
| Prix | $3.86 |
| Capitalisation | $365M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: AMN · CDNA · CSTL · DNA · DRIO · EVH · FLGT
Explorer le secteur: Healthcare · Medical - Diagnostics & Research
Plus de sections de MYGN: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions